Biology and Clinical Relevance of Acute Myeloid Leukemia Stem Cells.

ABSTRACT: Evidence for the cancer stem cell model was first demonstrated in xenotransplanted blood and bone marrow samples from patients with acute myeloid leukemia (AML) almost two decades ago, supporting the concept that a rare clonal and mutated leukemic stem cell (LSC) population is sufficient to drive leukemic growth. The inability to eliminate LSCs with conventional therapies is thought to be the primary cause of disease relapse in AML patients, and as such, novel therapies with the ability to target this population are required to improve patient outcomes. An important step towards this goal is the identification of common immunophenotypic surface markers and biological properties that distinguish LSCs from normal hematopoietic stem and progenitor cells (HSPCs) across AML patients. This work

SUBMITTER: Reinisch A 

PROVIDER: S-EPMC5516648 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature